Long-Acting In Situ Cancer Vaccines by Oncolytic STING-Activating Microgels.

Tan H, Guo J, Wang Y, Chen W, Zhong Z, Deng C

Small (Weinheim an der Bergstrasse, Germany)5 Aug 2025Cited by 4 (Europe PMC)

PMID40761011DOI10.1002/smll.202503561PepBankPUB-40761011

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

01AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In murine tumors, one intratumoral administration of LTX‑315 and diABZI microgels markedly promoted cytotoxic T-lymphocyte infiltration.
In plain wordsIn mice, LTX‑315 and diABZI microgels increased tumor infiltration by cytotoxic T cells.
Peptide
LTX-315
Outcome
IncreaseCytotoxic T-lymphocyte infiltration
Study
Mousen: not reported in source
Murine tumor models
Outcome group
Immune response · Cancer
Source sentences
Summary
One single intratumoral administration of OSAM markedly promoted the infiltration of cytotoxic T lymphocytes and natural killer cells, which combining with anti-CTLA-4 microgels afforded exceptional therapeutic benefits in several different murine tumor models with a cure rate of 40%-71%.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4076101103
02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In murine tumors, one intratumoral administration of LTX‑315 and diABZI microgels markedly promoted natural killer cell infiltration.
In plain wordsIn mice, LTX‑315 and diABZI microgels increased natural killer cell infiltration in tumors.
Peptide
LTX-315
Outcome
IncreaseNatural killer cell infiltration
Study
Mousen: not reported in source
Murine tumor models
Outcome group
Immune response · Cancer
Source sentences
Summary
One single intratumoral administration of OSAM markedly promoted the infiltration of cytotoxic T lymphocytes and natural killer cells, which combining with anti-CTLA-4 microgels afforded exceptional therapeutic benefits in several different murine tumor models with a cure rate of 40%-71%.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4076101104
03AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In murine tumor models, LTX‑315 and diABZI microgels combined with anti-CTLA-4 microgels achieved cure rates of 40%-71%.
In plain wordsIn mice, LTX‑315 and diABZI microgels with antibody microgels achieved tumor cure rates of 40%-71%.
Peptide
LTX-315
Outcome
Not applicableTumor cure rate
Study
Mousen: not reported in source
Murine tumor models
Outcome group
Tumor growth · Cancer
Measurements
Cure rate
40 to 71%
OSAM plus anti-CTLA-4 microgels
Source sentences
Summary
One single intratumoral administration of OSAM markedly promoted the infiltration of cytotoxic T lymphocytes and natural killer cells, which combining with anti-CTLA-4 microgels afforded exceptional therapeutic benefits in several different murine tumor models with a cure rate of 40%-71%.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4076101105
04AnimalNot a test of LTX-315 aloneOther designMechanism
In preclinical experiments, LTX‑315 and diABZI microgels significantly increased MHC I expression for more than one week.
In plain wordsIn preclinical experiments, LTX‑315 and diABZI microgels increased MHC I expression for more than one week.
Peptide
LTX-315
Outcome
IncreaseMHC I expression
Study
n: not reported in source
Outcome group
Immune response · Cancer
Source sentences
Summary
OSAM induced significant upregulation of MHC I and substantial activation of dendritic cells for more than one week.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4076101101
05AnimalNot a test of LTX-315 aloneOther designMechanism
In the tumor study, LTX‑315 and diABZI microgels activated dendritic cells for more than one week.
In plain wordsIn preclinical experiments, LTX‑315 and diABZI microgels activated dendritic cells for more than one week.
Peptide
LTX-315
Outcome
IncreaseDendritic cell activation
Study
n: not reported in source
Outcome group
Immune response · Cancer
Source sentences
Summary
OSAM induced significant upregulation of MHC I and substantial activation of dendritic cells for more than one week.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4076101102
06AnimalNot a test of LTX-315 aloneOther designPharmacokinetics
In preclinical experiments, OSAM sustained release of LTX‑315 and diABZI for more than 4 weeks.
In plain wordsIn preclinical experiments, the microgels released LTX‑315 and diABZI for more than 4 weeks.
Peptide
LTX-315
Outcome
Not applicableSustained payload release
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4076101106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.